You are here

After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?

After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?

Submitted by admin on October 1, 2024 - 9:52am

Source:

Pharma Voice

News Tags:

Atara Biotherapeutics

Headline:

After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?

snippet:

Atara Biotherapeutics scored a world-first approval for an off-the-shelf T cell therapy when the European Commission greenlit Ebvallo to treat an ultra-rare type of blood cancer in 2022.